• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Investor day reveals Carl Zeiss Meditec AG's plans

Article

Jena, Germany-During a presentation at Carl Zeiss Meditec AG's Investor Day in Munich, managers of the Strategic Business Units (SBUs) Surgical Ophthalmology, Ophthalmic Systems, and Neuro/ENT Surgery outlined their departments' strategies and challenges.

Jena, Germany-During a presentation at Carl Zeiss Meditec AG's Investor Day in Munich, managers of the Strategic Business Units (SBUs) Surgical Ophthalmology, Ophthalmic Systems, and Neuro/ENT Surgery outlined their departments' strategies and challenges.

The company also gave an overview of new products including the high-definition device system (Cirrus HD-OCT), operation microscope, (OPMI Pentero), and femtosecond laser (VisuMax), which was demonstrated during an eye exam to correct vision defects.

The company's IOL portfolio also was presented, which now covers the entire spectrum in the area of IOLs and ranges from simple, monofocal lenses for the treatment of cataracts to technically demanding multifocal and microincision lenses for refractive surgery.

"Overall, our goal was to give participants a better insight into our positioning as an integrated medical technology company," said Ulrich Krauss, chief executive officer and president of Carl Zeiss Meditec AG. "We wanted to present our individual growth drivers in the SBUs Surgical Ophthalmology, Ophthalmological Systems, and Neuro/ENT Surgery in a clear and tangible way. The discussion this prompted following the presentations showed us that this mission was successfully accomplished."

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.